<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.103061</article-id><article-id pub-id-type="publisher-id">TCM-42805</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210300000_13807474.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  太阴病论治结直肠癌围化疗期的感悟
  The Perception of the Treatment Method of the Taiyin Disease in the Peri-Chemotherapy Period of Colorectal Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>纪</surname><given-names>丽芝</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>梅</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>广州中医药大学第一附属医院，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>广州中医药大学，广东 广州</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>04</month><year>2021</year></pub-date><volume>10</volume><issue>03</issue><fpage>440</fpage><lpage>445</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  化疗在结直肠癌的分期治疗中具有较广泛的应用，且取得了公允的较大获益。但化疗在改善结直肠癌患者生存状况的同时，也造成了包括胃肠道反应在内的多种毒副作用，中医药的介入能有效地改善人体对化疗药物的耐受并提高化疗效果。师法经典，笔者发现《伤寒论》中的太阴病与结直肠癌患者围化疗期的病情存在病位、病性、病机上的相似，故在结直肠癌围化疗期的分期证治中，可借鉴太阴病的治则治法：温中为主，兼顾肝肾，此外还发现太阴病的时间规律对结直肠癌的时间化疗亦有启发，由此可见经典指导临床的意义及发掘经典价值的必要性。
  Chemotherapy has been widely used in staging treatment of colorectal cancer, and has achieved a fair and large benefit. However, chemotherapy has not only improved the survival condition of colorectal cancer patients, but also caused a variety of toxic and side effects including gastrointestinal reactions. TCM intervention can effectively improve the human body’s tolerance to chemotherapy drugs and improve the effect of chemotherapy. According to the classic method, we found that the condition of Taiyin disease in the typhoid theory and the condition of colorectal cancer patients in the peri-chemotherapy period are similar in the disease location and pathogenesis. Therefore, in the treatment of stage syndrome in the peri-chemotherapy period of colorectal cancer, the treatment method of Taiyin disease can be used for reference: temperature-centered, giving consideration to both liver and kidney. In addition, we also found that the regularity of the time of Taiyin disease is also enlightening to the time chemotherapy of colorectal cancer. Thus, it can be seen the significance of classical guidance in clinical practice and the necessity of exploring classical value. 
 
</p></abstract><kwd-group><kwd>伤寒论，太阴病，结直肠癌，化疗, Typhoid</kwd><kwd> Taiyin Disease</kwd><kwd> Colorectal Cancer</kwd><kwd> Chemotherapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>化疗在结直肠癌的分期治疗中具有较广泛的应用，且取得了公允的较大获益。但化疗在改善结直肠癌患者生存状况的同时，也造成了包括胃肠道反应在内的多种毒副作用，中医药的介入能有效地改善人体对化疗药物的耐受并提高化疗效果。师法经典，笔者发现《伤寒论》中的太阴病与结直肠癌患者围化疗期的病情存在病位、病性、病机上的相似，故在结直肠癌围化疗期的分期证治中，可借鉴太阴病的治则治法：温中为主，兼顾肝肾，此外还发现太阴病的时间规律对结直肠癌的时间化疗亦有启发，由此可见经典指导临床的意义及发掘经典价值的必要性。</p></sec><sec id="s2"><title>关键词</title><p>伤寒论，太阴病，结直肠癌，化疗</p></sec><sec id="s3"><title>The Perception of the Treatment Method of the Taiyin Disease in the Peri-Chemotherapy Period of Colorectal Cancer</title><p>Lizhi Ji<sup>1</sup>, Mei Jiang<sup>2</sup></p><p><sup>1</sup>Guangzhou University of Traditional Chinese Medicine, Guangzhou Guangdong</p><p><sup>2</sup>The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou Guangdong</p><p><img src="//html.hanspub.org/file/22-2270658x4_hanspub.png" /></p><p>Received: Feb. 7<sup>th</sup>, 2021; accepted: May 21<sup>st</sup>, 2021; published: May 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/22-2270658x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Chemotherapy has been widely used in staging treatment of colorectal cancer, and has achieved a fair and large benefit. However, chemotherapy has not only improved the survival condition of colorectal cancer patients, but also caused a variety of toxic and side effects including gastrointestinal reactions. TCM intervention can effectively improve the human body’s tolerance to chemotherapy drugs and improve the effect of chemotherapy. According to the classic method, we found that the condition of Taiyin disease in the typhoid theory and the condition of colorectal cancer patients in the peri-chemotherapy period are similar in the disease location and pathogenesis. Therefore, in the treatment of stage syndrome in the peri-chemotherapy period of colorectal cancer, the treatment method of Taiyin disease can be used for reference: temperature-centered, giving consideration to both liver and kidney. In addition, we also found that the regularity of the time of Taiyin disease is also enlightening to the time chemotherapy of colorectal cancer. Thus, it can be seen the significance of classical guidance in clinical practice and the necessity of exploring classical value.</p><p>Keywords:Typhoid, Taiyin Disease, Colorectal Cancer, Chemotherapy</p><disp-formula id="hanspub.42805-formula24"><graphic xlink:href="//html.hanspub.org/file/22-2270658x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-2270658x7_hanspub.png" /> <img src="//html.hanspub.org/file/22-2270658x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 结直肠癌化疗现状</title><p>发生于结肠上皮黏膜细胞的结肠癌是常见的消化道肿瘤，其每年的新发病例在世界范围内约占全部癌种的15% [<xref ref-type="bibr" rid="hanspub.42805-ref1">1</xref>]。而肠管下段的直肠癌 [<xref ref-type="bibr" rid="hanspub.42805-ref2">2</xref>] 亦以高发病率、高治疗难度、预后不良著称。根治性手术是大肠癌治疗的首选，但术后仍可能发生的复发和转移却是患者生存的主要威胁。如结肠癌III期患者出现淋巴结转移，其5年生存率仅不到30% [<xref ref-type="bibr" rid="hanspub.42805-ref3">3</xref>]。统计数据表明，结直肠癌患者在根治术后大约有一半会在5年内发生复发或转移 [<xref ref-type="bibr" rid="hanspub.42805-ref4">4</xref>]。所幸近几十年间，相比上世纪80年代，以5-氟尿嘧啶为基础的化疗已将中晚期结肠癌患者的死亡率降低了约30%，术后辅助化疗改善了结肠癌的无病生存率和总生存率，减少了30%左右结肠癌复发、转移相关危险的发生 [<xref ref-type="bibr" rid="hanspub.42805-ref5">5</xref>]。晚期结直肠癌患者采用姑息化疗方法的中位生存期也可长达2年 [<xref ref-type="bibr" rid="hanspub.42805-ref6">6</xref>]。肠癌化疗的广泛性和有效性已经得到公允，但化疗药物对机体的损伤也是不可避免的事实。</p><p>消化道不良反应是最常见的化疗毒副作用，发生率高达77.5%~97.4% [<xref ref-type="bibr" rid="hanspub.42805-ref7">7</xref>]。其主要症状为恶心呕吐、食欲不振、腹胀、腹泻、便秘等。呕吐腹泻等轻则影响患者生活质量、打击患者治疗信心，重则或导致水电解质紊乱、心肾功能不全、增加感染机会、引起化疗相关性败血症，甚至导致化疗药物减量、停用，治疗中止。恶心、呕吐、食欲不振的发生机制与 [<xref ref-type="bibr" rid="hanspub.42805-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42805-ref9">9</xref>] 化疗药物直接刺激胃肠道粘膜有关，该刺激导致肠嗜铬细胞释放5-羟色胺，后者作用于周围及中枢的5-羟色胺受体从而产生兴奋引起呕吐。腹泻等则因化疗药物损伤胃肠道粘膜，破坏屏障作用，导致上皮组织损伤、局部机会感染，产生刺激水、电解质分泌的因子，导致分泌与吸收机能紊乱，进而刺激水电解质的大量分泌，导致腹泻甚至脱水 [<xref ref-type="bibr" rid="hanspub.42805-ref10">10</xref>]。便秘的产生则可能和与化疗药物同时使用的止吐药物副作用相关，或和化疗药本身的神经毒性引起肠麻痹有关 [<xref ref-type="bibr" rid="hanspub.42805-ref11">11</xref>]。西医针对化疗产生的胃肠道毒副作用多采用对症处理方法，常用药物包括5-HT3受体拮抗剂、吩噻嗪类以及糖皮质激素等，但往往又因对症药物本身的毒副作用引发便秘、转氨酶升高、锥体外系反应和心脏毒性等新一轮的问题 [<xref ref-type="bibr" rid="hanspub.42805-ref12">12</xref>]。中医在为化疗减毒方面具有疗效确切、不良反应轻、能有效提高患者生存质量等优点 [<xref ref-type="bibr" rid="hanspub.42805-ref13">13</xref>]。有学者 [<xref ref-type="bibr" rid="hanspub.42805-ref14">14</xref>] 针对术后使用XELOX方案化疗的Ⅲ期结肠癌手术患者设计病例对照研究，结果表明中药与结肠癌辅助化疗的联合，在强化抑制癌细胞的同时，可明显减少化疗相关毒副反应的发生。可见中医药在结直肠癌的围化疗期非但有介入之必要，且具备相当优势。</p></sec><sec id="s6"><title>2. 结直肠癌与太阴病</title><p>衷中参西，师古不泥是结直肠癌中医诊疗的基本原则，若法《伤寒论》六经辨证之法，结直肠癌从病位、病性、病因、病机上与太阴病均存在共通之处。</p><p>《灵枢&#183;经脉篇》中提及足太阴脾经：起于大指之端，循指内侧白肉际，过核骨后，上内踝前廉，上踹内，循胫骨后，交出厥阴之前，上膝股内前廉，入腹，属脾络胃，上膈，挟咽，连舌本，散舌下；其支者，复从胃别上膈，注心中。脾经的走行从足走腹，通达上下，联络脾胃，然太阴病的病位虽与足太阴经的位置有关，却不与之完全重合。脾主大腹，脾主四肢，脾脏与胃腑相表里，故而太阴病的病位既包括腹部脾与胃肠之所，也涉及四肢躯体之末。结直肠癌的病位恰在太阴病部位，大腹之中，与胃腑相连，是消化系统的重要一环。</p><p>脾为阴脏，太阴之病亦多虚寒湿冷。太阴病的病症表现正如太阴病开篇的提纲证所列：“太阴之为病，腹满而吐，食不下，自利益甚，时腹自痛，若下之，必胸下结鞭”，以腹满、呕吐、厌食、腹痛、腹泻为主。故知太阴病的本质即是脾胃机能的虚衰，运化功能的减退，中阳失运，寒湿困脾。化疗在结直肠癌治疗中所产生的毒副作用，厌食恶心呕吐腹泻等胃肠道反应与太阴病的表现相同，病理上化疗致胃肠道粘膜的损伤刺激和太阴病的中阳之损病机亦可对应。有学者 [<xref ref-type="bibr" rid="hanspub.42805-ref15">15</xref>] 对780例大肠癌患者的复合证型进行拆分为单一证型后作回顾性研究，发现初诊患者的中医证型以气虚和脾虚最常见。另一学者对311例大肠癌患者进行中医证型调查，亦发现相似结果：脾气虚、脾胃虚弱两个证型的构成比均超过20% [<xref ref-type="bibr" rid="hanspub.42805-ref16">16</xref>]。可见结直肠癌的辨证分型与太阴病确有相当部分的重合，故针对结直肠癌围化疗期，尤其辨证属脾阳虚弱、寒湿中阻者可参照太阴病证治。</p></sec><sec id="s7"><title>3. 治则治法</title><p>《伤寒论》第358条：伤寒四五日，邪入太阴之时也。腹中痛，若不转气下趋者，属阳明也。今腹中痛，转气下趋少腹者，乃太阴欲作自利之候也。风寒之邪内传入里，若不能止于阳明则往往传入三阴，而太阴首当其冲，故而出现腹泻等症状。FOLFIRI方案是晚期结直肠癌的化疗一、二线方案，据调查，该方案引起的腹泻发生率高达50% [<xref ref-type="bibr" rid="hanspub.42805-ref17">17</xref>]，这是因为此方案中包含的氟尿嘧啶和伊立替康均有致化疗相关性腹泻的风险。伊立替康是一种可溶性喜树碱衍生物 [<xref ref-type="bibr" rid="hanspub.42805-ref18">18</xref>]，在体内细胞酶的作用下可转化为抗肿瘤活性更高的7-乙基-10-羟基喜树碱(SN-38)，后者在干扰DNA复制转录、消灭肿瘤细胞的同时也会损伤体内的正常组织，如同样细胞增殖活跃的肠粘膜，从而导致腹泻的发生。事实上，III~IV级迟发性腹泻的发生率在与伊立替康相关的化疗方案中可达6%~47% [<xref ref-type="bibr" rid="hanspub.42805-ref19">19</xref>]。迟发性腹泻是伊立替康所特有的，区别于以轻中度腹泻为主的早发性腹泻，是一种常见的剂量限制性毒性，严重时或导致水电解质紊乱甚至导致死亡 [<xref ref-type="bibr" rid="hanspub.42805-ref20">20</xref>]。化疗药善于攻伐而欠于固正，致使中焦之气受伤，寒湿内生，治本太阴。</p><p>《伤寒论》第277条：自利不渴者，属太阴，以其藏有寒故也，当温之，宜服四逆辈。太阴病治法主于温中，忌在攻下。一般认为，太阴病的主方应属理中丸(汤)为妥，温运中阳，健脾燥湿，恰符病机，然仲景一句“宜服四逆辈”却未得善解，自古医家曲为解释，难免牵强，以四逆辈方药虽有温中之理，却也包含附子温肾之机，似难合于太阴病治法。殊不知此法本于五行生化之理，土生于火，脾土生于命门火，陈氏《黄帝外经》早言：脾土之父母，不止一火也，心经之君火，包络、三焦、命门之相火，皆生之，然而君火之生脾土甚疏，相火之生脾土甚切，而相火之中命门之火，尤为最亲。《辨证录》治脾困之泻的奠土汤(白术、茯苓、砂仁、山药、人参、萝卜子、附子、半夏、破故纸)取用附子、破故纸补肾以温脾即是脉承于此。故曰太阴病治法实为温中顾下元，理中意未全。是以伊立替康致严重的迟发性腹泻若属中焦寒湿则可以理中化裁，虽未必加附子却以兼顾下元之治为正法。</p><p>《伤寒论》第279条：本太阳病，因尔腹满时痛者，属太阴也，桂枝加芍药汤主之；大实痛者，桂枝加大黄汤主之。此条论表病误下损及太阴之治。太阴病证属中阳之损，阴寒之盛，拟方温中不论反重用寒凉之芍药，古今医家或指为年久错书，或以为脾络瘀滞用之和血……种种意见，未能一论。其实芍药作用当以平肝来论，《本草新编》论芍药正以“平肝”为第一要义，以芍药能养肝血柔肝体，又微寒清肝火，补其不足，平其有余，是治肝最要之品。木旺乘土，土亏受乘，理之自然，误下损中，脾土亏损引遭肝木之克，故见腹痛，方以甘、枣、姜温养中土，桂枝疏肝，芍药平肝，从肝木治脾土，如《金匮要略》开篇所言：见肝之病，知肝传脾，当先实脾……正是木土相关，治当兼顾之明证。伤寒论第259条：伤寒发汗已，身目为黄，所以然者，以寒湿在里不解故也。以为不可下也，于寒湿中求之。此以太阴寒湿久滞不化，发生阴黄，从现代医学的角度，黄疸的发生往往责之肝胆疾患，此亦木土关联之病，因此太阴病的治疗需要适时兼顾肝木。对于结直肠癌而言，肝脏亦是癌灶转移的第一高发区，在所有结直肠癌患者的病程中，有超过一半的患者会出现肝转移，这也是结直肠癌患者死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.42805-ref21">21</xref>]。这与太阴病的木土相关相符，平肝之治亦应适时而早地加入。</p><p>结直肠癌围化疗期的中医治疗需分期辨治，早中期根治术后以减毒、改善症状、提高生活质量，延长无瘤生存期，降低复发率为主要目标，晚期姑息性化疗期间则以既病防变为主要治则，包括治疗原发灶的肝转移，以及化疗间歇期的维持治疗。具体除了口服理中汤丸诸演绎方药：参苓白术散、四逆汤、五苓散、桂枝人参汤等酌加顾及肝肾之品外，还可本诸温里散寒的治则，选用经穴刺激方法，如针刺、外敷、按摩、导引等等。</p></sec><sec id="s8"><title>4. 时间用药</title><p>《伤寒论》第275条：太阴病欲解时，从亥至丑上。脾为太阴，应于亥、子、丑时而得阳生之气，则正旺邪退为欲解之时。“生物钟”是近些年的生命科学研究热点，如何利用细胞昼夜节律，调整化疗用药时间，避开正常细胞合成DNA的高峰使用细胞毒药物，由此提高药物疗效并减少毒副作用即是“时间化疗”。研究表明，在疗效或耐受性方面，有大约30种抗癌药物受昼夜节律的影响而波动，这种波动范围甚至可达50%以上 [<xref ref-type="bibr" rid="hanspub.42805-ref22">22</xref>]。目前认为，晚期结直肠癌采用昼夜节律性用药方案相比传统以5-FU为主的联合化疗方案，客观有效率有2-6倍的提高，中位生存期有50%的提高，毒副反应亦降低约2~10倍。人体内的二氢嘧啶脱氢酶(Dehydropyrimidine dehydrogenase, DPD)是一种限速酶，它能将5-氟尿嘧啶分解，从而提高机体对5-氟尿嘧啶的耐受性。从午夜到早上10:00，DPD的活性最强，高出其他时间段近50%，故根据DPD的节律调整用药时间可大大提高5-氟尿嘧啶的耐受量，每日4:00 am左右5-氟尿嘧啶的血药浓度最高同时机体也具有较高耐受性 [<xref ref-type="bibr" rid="hanspub.42805-ref10">10</xref>]。此时间与太阴病的恢复时间恰相接近，值得深思。</p></sec><sec id="s9"><title>5. 案例</title><p>潘某，女，65岁，就诊时间：2020-11-27主诉：结肠癌术后2月余。</p><p>患者于2020-5-7在当地医院行胃肠镜检查并钳取结肠组织送检病理，结果提示：右半结肠腺癌，乙状结肠腺管状腺瘤，腺上皮中度不典型增生。2020-5-11行PET-CT检查，结果示：右半结肠管壁偏心性增厚并形成软组织肿块影，考虑结肠癌并临近肠系膜及腹膜受侵，病灶累及盲肠、阑尾及回肠末端；左侧锁骨上、胸锁乳突肌下、肠系膜、腹主动脉旁及双侧髂血管旁多发肿大淋巴结，考虑淋巴结转移。2020-5-14行基因检测结果示：K-ras外显子2/3/4(-)、N-Ras外显子2/3/4(-)、PIK3CA外显子20(-)、B-raf外显子15(-)，患者于2020-5-14行1程贝伐珠单抗 + XEL0X方案化疗后，又行3程贝伐珠单抗 + FOLFOX6方案化疗，于2020-8-26行右半结肠切除 + 大网膜部分切除 + 腹腔内肿物切除 + 肠粘连松解 + 腹腔穿刺置术，术后又行2程FOLFOX6方案化疗及1程贝伐珠单抗 + XEL0X方案化疗，末次化疗时间为2020-11-2，拟下次化疗时间为：2020-11-30。</p><p>刻症：神清，精神一般，面白唇色淡，易疲乏，畏寒，纳差，眠可，大便日行2~3次，质稀，小便调，舌淡嫩，偏黯，苔薄白，脉细弱稍兼涩。</p><p>四诊合参，考虑患者术后化疗后损伤中阳，寒湿內生，脾胃纳化失常，故见纳差腹泻诸症，舌淡嫩脉细弱亦为中气虚弱，气血生化不足，反生湿邪之象，舌象偏黯，脉象兼涩则本于癌瘤瘀滞之机，化疗前夕，攻伐暂息，姑从太阴论治，温中兼益肾。方药如下：</p><p>白术30 g 茯苓15 g 炙甘草6 g 太子参15 g</p><p>菟丝子15 g 枸杞子15 g 覆盆子10 g 陈皮10 g</p><p>五指毛桃30 g鸡血藤15 g 丹参10 g 建曲10 g</p><p>炒麦芽10 g 焦山楂10 g</p><p>共3剂(2020-11-27至2020-11-29)</p><p>本方以白术为君，健脾益气且利腰脐之气而益肾，臣以菟丝子、枸杞子、覆盆子等平补肾气以熏蒸脾胃，以茯苓渗湿，太子参、五指毛桃益气，陈皮理气，建曲、山楂、麦芽消食和胃，炙甘草和诸药，更加鸡血藤、丹参条畅瘀滞之血，润养匮乏之阴，有养肝体和肝气以平木之意。虽不见理中而理中之意备矣，可谓太阴病正治。</p><p>2020-11-30复诊</p><p>患者精神转佳，胃纳好转，口稍干，大便日一行，成形，小便调，眠可。</p></sec><sec id="s10"><title>6. 总结</title><p>化疗是结直肠癌分期治疗的常规选择，在改善结直肠癌患者生存状况的同时，化疗的毒副作用也不可避免地对人体造成损伤，其中以胃肠道反应最为常见，除了西医药的常规对症处理，中医药的介入也能获得较为确切的疗效且不良反应轻，能有效地改善人体对化疗药物的耐受，提高化疗效果。结直肠癌患者在围化疗期的病理状态等与太阴病有诸多相似之处，故在治疗思路上亦可互通，太阴病的治则治法：温中为主，兼以益肾平肝，对于结直肠癌患者的分期论治有较大的启发意义，太阴病的时间规律对结直肠癌的时间化疗亦有提示作用。《伤寒论》虽为汉代著书，然历久弥新，直到今天，它对于包括肿瘤在内的多种疾病治疗仍具有极深远的指导意义，如何发掘经典价值，活用理论造福临床是每一个中医临床医生都应该深思的。</p></sec><sec id="s11"><title>文章引用</title><p>纪丽芝,蒋 梅. 太阴病论治结直肠癌围化疗期的感悟The Perception of the Treatment Method of the Taiyin Disease in the Peri-Chemotherapy Period of Colorectal Cancer[J]. 中医学, 2021, 10(03): 440-445. https://doi.org/10.12677/TCM.2021.103061</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42805-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Leijssen, L.G.J., Dinaux, A.M., Taylor, M.S., Deshpande, V., Hiroko, K., Bordeianou, L.G., et al. (2019) Perineural Invasion Is a Prognostic but Not a Predictive Factor in Nonmetastatic Colon Cancer. Diseases of the Colon &amp; Rectum, 62, 1212-1221. &lt;br&gt;https://doi.org/10.1097/DCR.0000000000001450</mixed-citation></ref><ref id="hanspub.42805-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">魏哲威, 张常华, 余捷, 吴菁, 何裕隆. 含奥沙利铂辅助化疗方案治疗结直肠癌可切除肝转移的预后分析[J]. 热带医学杂志, 2018, 18(9): 1156-1159, 1181.</mixed-citation></ref><ref id="hanspub.42805-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ouyang, M., Luo, Z., Wu, J., Zhang, W., Tang, S., Lu, Y., et al. (2019) Comparison of Outcomes of Complete Mesocolic Excision with Conventional Radical Resection Performed by Laparoscopic Approach for Right Colon Cancer. Cancer Management and Research s, 25, 8647-8656. &lt;br&gt;https://doi.org/10.2147/CMAR.S203150</mixed-citation></ref><ref id="hanspub.42805-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">吴福红, 孙元珏. XELOX与FOLFOX4方案治疗晚期结直肠癌的临床研究[J]. 医学信息(下旬刊), 2011, 24(18): 3-5.</mixed-citation></ref><ref id="hanspub.42805-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">徐俊, 陈旭. 结肠癌辅助化疗的研究进展[J]. 医学综述, 2017, 23(20): 4039-4044.</mixed-citation></ref><ref id="hanspub.42805-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">徐瑞华, 邱妙珍. 晚期结直肠癌化疗的研究进展[J]. 癌症, 2008, 27(6): 661-666.</mixed-citation></ref><ref id="hanspub.42805-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D. and Fu, J. (2014) Symptom Clusters and Quality of Life in China Patients with Lung Cancer Undergoing Chemotherapy. African Health Sciences, 14, 49-55. &lt;br&gt;https://doi.org/10.4314/ahs.v14i1.8</mixed-citation></ref><ref id="hanspub.42805-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">郭兴罡, 赵智辅, 陈杰, 庄海英. 顺铂化疗过程中联合应用大剂量止吐药预防胃肠道反应[J]. 黑龙江医学, 2000(4): 30.</mixed-citation></ref><ref id="hanspub.42805-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">林万隆, 陈强. 奥沙利铂的药理作用及临床应用[J]. 中国肿瘤临床, 2000, 27(11): 872-874.</mixed-citation></ref><ref id="hanspub.42805-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">潘建军. 肿瘤放化疗所引起腹泻两种治疗方法比较分析[J]. 求医问药(下半月), 2011, 9(11): 563.</mixed-citation></ref><ref id="hanspub.42805-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">朱一玢. 时辰化疗结合择时用药缓解肠癌术后化疗胃肠反应的研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2013.</mixed-citation></ref><ref id="hanspub.42805-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">曹迪, 张亚密, 全建峰. 中医药改善化疗毒副反应的研究进展[J]. 中国中医急症, 2020, 29(7): 1302-1305, 1308.</mixed-citation></ref><ref id="hanspub.42805-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kumamoto, K., Nakachi, Y., Mizuno, Y., Yokoyama, M., Ishibashi, K., Kosugi, C., et al. (2019) Expressions of 10 Genes as Candidate Predictors of Recurrence in Stage Ⅲ Colon Cancer Patients Receiving Adjuvant Oxaliplatin-Based Chemotherapy. Oncology Letters, 18, 1388-1394. &lt;br&gt;https://doi.org/10.3892/ol.2019.10437</mixed-citation></ref><ref id="hanspub.42805-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">徐萌, 王勇, 张梅, 胡金鹏, 李平. Ⅲ期结肠癌术后辅助化疗联合中药治疗的疗效研究[J]. 安徽医学, 2020, 41(3): 273-276.</mixed-citation></ref><ref id="hanspub.42805-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">林胜友, 沈敏鹤, 舒静娜, 蓝继. 780例大肠癌中医证型分类 特征的回顾性分析[J]. 浙江中医药大学学报, 2011, 35(3): 322-324.</mixed-citation></ref><ref id="hanspub.42805-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">侯风刚, 岑怡, 贯剑, 朱凌云, 殷晓聆, 刘静. 肠癌中医症状证候临床调查分析[J]. 辽宁中医药大学学报, 2010, 12(1): 32-34.</mixed-citation></ref><ref id="hanspub.42805-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Xu, S.Z. (2014) Clinical Study on Chemotherapy Induced Diarrhea in Colorectal cancer Patients. Zhejiang University, Hangzhou.</mixed-citation></ref><ref id="hanspub.42805-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">梅丹, 陆俊国, 顾海娟, 郭小红, 徐艳艳, 倪美鑫. 伊立替康化疗相关性腹泻发生的特点与危险因素分析[J]. 中国医院药学杂志, 2019, 39(2): 191-195.</mixed-citation></ref><ref id="hanspub.42805-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., et al. (2014) Guidance on the Management of Diarrhoea during Cancer Chemotherapy. The Lancet Oncology, 15, e447-e460.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(14)70006-3</mixed-citation></ref><ref id="hanspub.42805-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Q.Y., Wang, H.L., Wu, T., et al. (2012) A Case of Serious Adverse Effect Induced by Irinotecan. Chinese Journal of Pharmaceuticals, 32, 733-735.</mixed-citation></ref><ref id="hanspub.42805-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">张宇涛. 结直肠癌的治疗进展[J]. 山西医药杂志, 2020, 49(5): 535-536.</mixed-citation></ref><ref id="hanspub.42805-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Levi, F. (1999) Caner Chronotherapy. Journal of Pharmacy and Pharmacology, 51, 891-898.  
&lt;br&gt;https://doi.org/10.1211/0022357991773302</mixed-citation></ref></ref-list></back></article>